Asia Pacific CAR T-Cell Therapy Market (2026-2031)
The Asia Pacific CAR T-Cell Therapy Market was valued at $10.3 Million in 2026 and projected to reach to $18.6 Million by 2031, representing a compound annual growth rate of 12.7%. The Asia Pacific CAR T-Cell Therapy Market is positioned for substantial growth as healthcare systems modernize and oncology treatment paradigms shift toward precision medicine.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Asia Pacific CAR T-Cell Therapy Market Trends and Insights
- Asia Pacific represents a critical growth region for CAR T-cell immunotherapies, driven by increasing cancer prevalence, rising healthcare investments, and expanding access to advanced treatment modalities across the region.
- The 12.7% compound annual growth rate reflects Asia Pacific's accelerating adoption of precision oncology solutions and strengthening regulatory frameworks that support cell therapy commercialization. Asia Pacific's market growth is underpinned by growing patient populations, improving healthcare infrastructure, and strategic partnerships between regional manufacturers and global CAR T-cell developers.
- Between 2026 and 2031, Asia Pacific is expected to capture significant market share as countries including China, Japan, South Korea, and India enhance their biopharmaceutical capabilities and reimbursement policies.
- The region's competitive advantage lies in manufacturing scale, cost efficiency, and emerging clinical expertise in cell therapy delivery. Key market participants in Asia Pacific are investing heavily in manufacturing facilities, clinical trial networks, and patient access programs to capitalize on the region's growth potential.
- Asia Pacific's trajectory through 2031 positions it as a pivotal market for global CAR T-cell therapy expansion, with increasing collaboration between academic institutions and commercial entities driving innovation and market penetration..
Key Market Statistics
- CAGR (2026-2031) 12.7% CAGR
- Market Size, 2026 ~USD 10.3 Million
- Forecast, 2031 ~USD 18.6 Million
- Geography Asia Pacific
Asia Pacific CAR T-Cell Therapy Market Overview
Rapid Market Expansion :
Asia Pacific CAR T-Cell Therapy Market is projected to grow from $10.3 million in 2026 to $18.6 million by 2031, representing a robust 12.7% CAGR, driven by increasing adoption of personalized cancer immunotherapies across the region.
Rising Cancer Burden :
Escalating cancer prevalence across Asia Pacific nations, particularly in China, Japan, and India, is fueling demand for advanced treatment options like CAR T-cell therapies as standard care protocols evolve.
Healthcare Investment Growth :
Governments and private healthcare systems across Asia Pacific are significantly increasing investments in oncology infrastructure, clinical research facilities, and biopharmaceutical manufacturing capabilities to support CAR T-cell therapy development and commercialization.
Regulatory Pathway Acceleration :
Streamlined regulatory approvals and expedited pathways for advanced therapies in key Asia Pacific markets are enabling faster market entry and broader patient access to CAR T-cell immunotherapies.
Asia Pacific CAR T-Cell Therapy Market Dynamics
- Key drivers include rising cancer incidence, expanding middle-class populations with improved healthcare access, and increasing collaboration between regional biotech firms and global CAR T-cell developers.
- Japan and China are emerging as innovation hubs, while India represents significant untapped potential due to its large patient population and cost-effective manufacturing capabilities. By 2031, Asia Pacific is expected to capture an increasingly larger share of the global CAR T-cell market as manufacturing localization reduces costs and regulatory harmonization improves market accessibility.
- Strategic partnerships, technology transfer agreements, and investment in clinical trial infrastructure will accelerate adoption across the region, positioning Asia Pacific as a critical growth engine for the global CAR T-cell therapy industry..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Asia Pacific CAR T-Cell Therapy Market valued at $10.3 million in 2026, expanding to $18.6 million by 2031 at 12.7% CAGR
- Asia Pacific's growth driven by rising cancer incidence, healthcare infrastructure improvements, and regulatory support for cell therapies
- Asia Pacific countries including China, Japan, and South Korea are establishing manufacturing and clinical capabilities to meet regional demand
- Asia Pacific represents a high-potential market for global CAR T-cell developers seeking geographic diversification and cost-efficient production
CAR T-Cell Therapy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CD19/20 (Target) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 13.7% from 2026 to 2031 |
| Largest Segment | CD19 (Target) |
| Market Size Base Year (Billions) | ~USD 7.25 (2026) |
| Revenue Forecast (Billions) | ~USD 13.78 (2031) |
| Segments Covered | Product, Target, Indication |
Asia Pacific CAR T-Cell Therapy Market Report Segmentation
3 segment dimensions are covered across the global market.
By Product
- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Other Products
- Tecartus
- Yescarta
By Target
- Bcma
- Cd19
- Cd19/20
- Cd7
- Other Targets
By Indication
- Acute Lymphoblastic Leukemia (All)
- B-Cell Lymphoma (Bcl)
- Multiple Myeloma
- Other Indications
Target Audience
- Biopharmaceutical Companies : CAR T-cell developers and oncology-focused pharma firms need Asia Pacific market intelligence to prioritize market entry, allocate R&D resources, and develop region-specific commercialization strategies.
- Healthcare Investors & PE Firms : Investment professionals require detailed Asia Pacific market data to identify high-potential biotech targets, assess regional growth opportunities, and evaluate portfolio companies' expansion strategies in the region.
- Hospital & Healthcare Systems : Healthcare administrators and oncology centers across Asia Pacific need market insights to plan CAR T-cell therapy program launches, budget for infrastructure, and understand competitive positioning.
- Medical Device & Diagnostics Companies : Suppliers of manufacturing equipment, biomarker testing, and supportive care solutions require Asia Pacific market data to identify partnership opportunities and develop region-tailored product offerings.
- Government & Policy Makers : Healthcare policymakers and regulatory agencies across Asia Pacific need market intelligence to inform reimbursement policies, clinical trial frameworks, and strategic healthcare investment decisions.
Key Companies in the Asia Pacific CAR T-Cell Therapy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| JOHNSON & JOHNSON | United States | Public Company | Oncology and Immunology (Innovative Medicine),Neuroscience, Cardiovascular & Metabolism, Pulmonary Hypertension, Infectious Diseases,Surgery and Interventional (instrumentation, energy, stapling, wound closure, biosurgery, robotic and digital), |
| GILEAD SCIENCES, INC. | United States | Public Company | HIV portfolio (Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo),Liver disease and other antivirals (Epclusa, Livdelzi, Vemlidy, AmBisome),COVID-19 (Veklury), |
| BRISTOL-MYERS SQUIBB COMPANY | United States | Public Company | Eliquis (anticoagulation),Immuno-oncology (Opdivo, Yervoy, Opdualag, Opdivo Qvantig),Hematology (Revlimid, Pomalyst/Imnovid, Reblozyl, Abecma, Breyanzi), |
| NOVARTIS AG | Switzerland | Public Company | Oncology & Hematology (Kisqali, Tafinlar+Mekinist, Jakavi, Pluvicto, Lutathera, Scemblix, Fabhalta),Immunology & Neuroscience (Cosentyx, Xolair, Ilaris, neurology assets),Cardiovascular, Renal & Metabolic (Entresto, Leqvio, other CVRM), |
| AUTOLUS THERAPEUTICS | United Kingdom | Public Company | CD19 CAR-T franchise (AUCATZYL / obe-cel – oncology),Autoimmune CD19 programs (obe-cel in SLE, MS, lupus nephritis),Next-generation oncology pipeline (AUTO1/22, AUTO8, AUTO6NG), |
| JW (CAYMAN) THERAPEUTICS CO., LTD. | China | Public Company | Commercial and late-stage CAR-T for hematologic malignancies (Carteyva, JWCAR201, JWCAR239),Autoimmune indications (relma-cel for SLE and related programs),Solid tumor pipeline (JWATM204/214/203/213, JWTCR001, JWCAR031), |
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | China | Public Company | Zevor-cel (CT053) – BCMA CAR-T for R/R multiple myeloma,Autologous solid-tumor CAR-T (CT041, CT011, CT071, CT0590/CT0596),Autoimmune and B-cell malignancy pipeline (KJ-C2219, KJ-C2320, KJ-C2529), |
| CARTESIAN THERAPEUTICS, INC. | United States | Public Company | Descartes-08 (autoimmune and rare pediatric indications),Descartes-15 (multiple myeloma),Platform and other mRNA cell therapy programs/services, |
| LYELL IMMUNOPHARMA, INC. | United States | Public Company | Hematologic CAR T programs (ronde-cel and platform),Solid tumor CAR T programs (LYL273 and related),Platform technologies and enabling IP (c-Jun, NR4A3 KO, Epi-R, CD62L enrichment), |
JOHNSON & JOHNSON
Johnson & Johnson is a diversified healthcare company founded in 1886 and headquartered in the United States. With 138,200 employees, it operates as a public company serving global markets.
GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a United States-based biopharmaceutical company founded in 1987. The public company employs 17,000 people and focuses on developing innovative therapeutics.
BRISTOL-MYERS SQUIBB COMPANY
Bristol-Myers Squibb Company is a pharmaceutical company established in 1887 in the United States. As a public company with 32,500 employees, it develops and manufactures pharmaceutical products.
NOVARTIS AG
Novartis AG is a Swiss multinational pharmaceutical company founded in 1996. The public company employs 75,267 people and operates globally in the healthcare sector.
AUTOLUS THERAPEUTICS
Autolus Therapeutics is a United Kingdom-based biopharmaceutical company founded in 2014. The public company has 753 employees and focuses on cell therapy development.
JW (CAYMAN) THERAPEUTICS CO., LTD.
JW (Cayman) Therapeutics Co., Ltd. is a China-based pharmaceutical company founded in 2016. The public company employs 314 people and operates in the therapeutic development sector.
CARSGEN THERAPEUTICS HOLDINGS LIMITED
Carsgen Therapeutics Holdings Limited is a China-based biopharmaceutical company founded in 2014. The public company has 355 employees and specializes in cell therapy development.
CARTESIAN THERAPEUTICS, INC.
Cartesian Therapeutics, Inc. is a United States-based public biopharmaceutical company with 75 employees. The company specializes in cell therapy and therapeutic development.
LYELL IMMUNOPHARMA, INC.
Lyell Immunopharma, Inc. is a United States-based public immunotherapy company founded in 2018. The company has 161 employees and develops cell-based immunotherapies.
Countries within Asia Pacific - compare and drill down
| Country | 2025 size (native) |
|---|---|
| China | USD Million |
| Japan | USD 18.6 Million |
| India | USD Million |
| Australia | USD Million |
| South Korea | USD Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Sizing & Forecasts : Obtain precise market valuations for Asia Pacific CAR T-Cell Therapy with detailed 2026-2031 projections, enabling accurate budget allocation and investment planning specific to this high-growth region.
- Country-Level Intelligence : Access granular market data for key Asia Pacific nations including Japan, China, India, Australia, and South Korea, identifying which markets offer the highest growth potential and fastest adoption rates.
- Competitive Landscape Analysis : Understand regional competitive dynamics, local player strategies, and market consolidation trends unique to Asia Pacific, informing go-to-market strategies and partnership opportunities.
- Regulatory & Reimbursement Insights : Gain clarity on Asia Pacific regulatory pathways, pricing strategies, and reimbursement frameworks that directly impact market entry timelines and commercial viability across different countries.
- Growth Driver Identification : Identify region-specific growth catalysts including healthcare infrastructure investments, clinical trial expansion, manufacturing localization, and patient population dynamics driving CAR T-cell adoption in Asia Pacific.
Frequently asked questions
What is the projected market size for CAR T-Cell Therapy in Asia Pacific by 2031?
Asia Pacific's CAR T-Cell Therapy Market is projected to reach $18.6 million by 2031, growing from $10.3 million in 2026.
What is the CAGR for CAR T-Cell Therapy in Asia Pacific?
Asia Pacific's CAR T-Cell Therapy Market is expected to grow at a compound annual growth rate of 12.7% between 2026 and 2031.
Which countries in Asia Pacific are leading CAR T-cell therapy adoption?
China, Japan, South Korea, and India are among the leading countries in Asia Pacific driving CAR T-cell therapy adoption through manufacturing investments and clinical infrastructure development.
What factors are driving growth in Asia Pacific's CAR T-Cell Therapy Market?
Key growth drivers in Asia Pacific include rising cancer prevalence, expanding healthcare investments, improving regulatory frameworks, and increasing partnerships between regional and global biopharmaceutical companies.
How does Asia Pacific's CAR T-Cell Therapy Market compare to global growth rates?
Asia Pacific's 12.7% CAGR is slightly below the global average of 13.7%, reflecting the region's emerging market status while still demonstrating strong growth momentum through 2031.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
CAR T-Cell Therapy Market Size: Bottom-up Approach and Top-down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CAR T-cell therapy is a treatment method wherein a patient’s T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient’s bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is known as a chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapeutic purposes.
Key Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations (CROs)
- Regulatory Authorities
- Healthcare Providers
- Patients and Patient Advocacy Groups
- Investors and Venture Capital Firms
- Research & Development Companies
- Research Laboratories & Academic Institutes.
- Market Research & Consulting Firms
Report Objectives
- To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
- To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at the global level
- To provide detailed information regarding the major drivers, restraints, opportunities, and challenges, influencing the market growth
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
- To provide an overview of the market with specialized analysis such as trends/disruptions impacting customers’ business, pricing analysis, value/ supply chain analysis,ecosystem analysis, technology analysis, patent analysis, key conferences & events 2026-2027, regulatory landscape, Porter’s five forces analysis, key stakeholders and buying criteria, and investment and funding scenario
Available customizations:
- With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe CAR T-cell therapy market, by country
- Further breakdown of the Rest of Asia Pacific CAR T-cell therapy market, by count
Company Information
- Detailed analysis and profiling of additional market players (up to five
Segment Analysis
- Cross-segment analysis
Get the Full CAR T-Cell Therapy Market Report
Full forecast, segment splits, and company analysis for all CAR T-Cell Therapy Market.
- US CAR T-Cell Therapy Market
- Canada CAR T-Cell Therapy Market
- Germany CAR T-Cell Therapy Market
- UK CAR T-Cell Therapy Market
- France CAR T-Cell Therapy Market
- Italy CAR T-Cell Therapy Market
- Spain CAR T-Cell Therapy Market
- China CAR T-Cell Therapy Market
- Japan CAR T-Cell Therapy Market
- India CAR T-Cell Therapy Market
- Australia CAR T-Cell Therapy Market
- South Korea CAR T-Cell Therapy Market
- Brazil CAR T-Cell Therapy Market
- UAE CAR T-Cell Therapy Market
- Rest Of Europe CAR T-Cell Therapy Market
- Rest Of Asia Pacific CAR T-Cell Therapy Market
- Rest Of Latin America CAR T-Cell Therapy Market
- GCC Countries CAR T-Cell Therapy Market
- Rest Of Middle East CAR T-Cell Therapy Market
- Kingdom Of Saudi Arabia CAR T-Cell Therapy Market
- Rest Of GCC Countries CAR T-Cell Therapy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report